FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| C. 20549 |
|----------|
| |

| heck this box if no longer subject to |
|---------------------------------------|
| ection 16. Form 4 or Form 5 |
| bligations may continue. See |
| |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* WEISS MICHAEL S | | | | 2. Issuer Name and Ticker or Trading Symbol TG THERAPEUTICS, INC. [TGTX] | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) | | | | | | | | |
|--|--|---------|-------------------|--|---------|---|-------------------------|-------------------------------------|------|---|------------------------------------|--------------|---|--|---|----------------------|--|--|----------|--|--|
| WEISS MICHAEL S | | | | | | | | | | | - | | | X | Direc | ctor | 2 | X 10% C | wner | | |
| (Last) (First) (Middle) | | | | | 3. D | Date of Earliest Transaction (Month/Day/Year) | | | | | | | | X | Offic belov | er (give title w) | | Other below) | (specify | | |
| 3 COLUMBUS CIRCLE | | | | | 06/ | 06/04/2015 | | | | | | | | See Remarks | | | | | | | |
| 15TH FLOOR | | | | | | | | | | | | | | | | | | | | | |
| (Cturt) | | | | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | |
| (Street) NEW YO | ORK N | Y 1 | .0019 | | | | | | | | | | | | X Form filed by One Reporting Person | | | | | | |
| | | | | | | | | | | | | | | | Form filed by More than One Reporting Person | | | | | | |
| (City) | (St | ate) (2 | Zip) | | | | | | | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date) | | | | | ar) i | 2A. Deemed Execution Date, if any (Month/Day/Year) | | Transaction Dispose Code (Instr. 5) | | rities Acquired (A) ed Of (D) (Instr. 3, | | | , 4 and S B O | | 5. Amount of Securities Beneficially Owned Following Reported | | ownership m: Direct or Indirect Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | Code V Amount (A) or (D) | | | Pric | e | Transaction(s) (Instr. 3 and 4) | | | | (11341. 4) | | | | | | |
| COMMON STOCK 06/ | | | | 06/04 | /2015 | 5 | | | A | | 337,257(1) | | A S | | \$0 8,72 | | 26,633 ⁽²⁾ | | D | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) | | | Date, sy/Year) | Transaction of Code (Instr. Deriv | | r osed) :. 3, 4 | 6. Date Expirat (Month) | on Da Day/Y | | Amount of Securities Underlying Derivative Security (Instr. and 4) | | ount nber | int er | | derivative Securities | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |

Explanation of Responses:

1. Reflects a grant of restricted shares that will vest according to the following schedule: 25% on January 1, 2018; 25% on January 1, 2019; and 50% on the later to occur of: (a) the date that the Company's Market Capitalization is \$100 million greater than the Market Capitalization on December 30, 2014 and (b) the January 1, 2020. Mr. Weiss elected to defer the 337,257 shares from a larger grant of 605,660 shares on December 30, 2014.

2. Includes shares of restricted Common Stock, which vest over various time periods. Includes 33,334 warrants to purchase Common Stock at \$2.25, exercisable through December 31, 2016. Finally, also included in Mr. Weiss' beneficial ownership are 4,524,560 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.

Remarks:

Executive Chairman, Interim CEO and President

/s/ Michael Weiss 06/05/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.